4002 Basel, ch
+41 (61) 316-8929
Lonza's Ibex™ Solutions to Support Genmab's Growing Clinical PortfolioBasel, )
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
Lonza’s Ibex™ Develop will enable Genmab to support their expanding pipeline demand for product across all clinical phases and towards potential launch
Flexible asset management designed to provide secure capacity for Genmab across their portfolio of candidates
Quote from Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech:
”Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years. Genmab’s extensive pipeline is an opportunity for us to combine the speed and flexibility of our Ibex Solutions with the know-how needed to manufacture pioneering molecular formats.”
Lonza today announced an extension to its partnership with Genmab to cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline. Lonza’s Ibex Solutions in Visp (CH) is designed to provide Genmab with the flexibility and speed they need to take their candidates towards IND and commercialization.
Genmab and Lonza have a longstanding relationship, having worked together on multiple antibody-based programs since 2002.
Lonza’s Ibex Design offering enables Genmab to take their candidates from gene to IND in 12 months and then move to reserved manufacturing capacity in Ibex Develop for clinical manufacturing and BLA submission when Genmab needs it. The agreement aims to provide Genmab with security of supply and to enable Genmab to move rapidly into clinical manufacturing with the flexibility needed to manage an extensive pipeline through the demands of clinical trials.
The new agreement will cover development and clinical manufacturing of drug substance and drug product for certain programs in Genmab’s pre-clinical and clinical pipeline. These include more complex molecular formats developed using Genmab’s DuoBody® technology.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
sults may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.